Qiagen QIAseq NGS Products
Qiagen has launched its QIAseq NGS products, which use proprietary "digital NGS" technology. Digital NGS utilizes unique molecular indices (UMIs) that allow for more accurate quantification and detection of molecular variants across all sequencing platforms, the company said. The QIAseq products include: QIAseq Targeted DNA panels, which combine UMIs and unique chemistry to detect low-frequency gene variants; QIAseq Targeted RNAscan panels, which incorporate UMIs into sequencing of RNA-derived libraries; QIAseq miRNA NGS kits, which solve major issues in workflow and contamination of unwanted sequencing reads; and QIAseq Targeted RNAseq kits, which utilize UMIs for accurate gene expression quantitation of up to 1,000 targets from as little as 10ng of RNA.
SeraCare IQ NGS QC Management Software for Clinical Laboratories
SeraCare Life Sciences has launched its IQ NGS QC management software, a cloud-based software tool designed to help labs easily track, trend, and report all their NGS quality control metrics for CAP and CLIA audits. The software allows labs to rapidly generate QC performance reports, including Levey-Jennings charts for any tracked variant. It flexibly conforms to any laboratory QC workflow and can help prevent errors by allowing labs to flag out of spec readings on QC materials, instruments, and reagents, the company said.
Transgenomic CLIA EGFR C797S Mutation Test
Transgenomic has made its EGFR C797S Mutation Detection assay available for clinical use through its CLIA laboratory in Omaha, Nebraska. The test, launched for research use earlier this year and based on the company's ICE COLD-PCR technology, detects the presence of the EGFR C797S mutation associated with resistance to third-generation tyrosine kinase inhibitor therapies for non-small cell lung cancer. It is available as a solo assay and also in three combination panels that include other EGFR mutations, the company said.
For more new products and services, please visit the New Products page on our website.